Can-Fite BioPharma (CANF) Treasury Shares (2013 - 2017)

Can-Fite BioPharma's (CANF) quarterly Treasury Shares came in at $970000.0 in Q4 2016, up 204.86% on a QoQ basis from -$925000.0 in Q3 2015.

Can-Fite BioPharma (CANF) Treasury Shares (2013 - 2017) Analysis & Trends

Can-Fite BioPharma (CANF) has 4 years of Treasury Shares data on file, last reported at $970000.0 in Q4 2016.

Quarterly Treasury Shares changed N/A year-over-year to $970000.0 in Q4 2016, while the trailing twelve-month figure through Dec 2016 was $970000.0 (changed N/A YoY) and the FY2016 annual result came in at $970000.0, changed N/A from the prior year.
Treasury Shares advanced to $970000.0 in Q4 2016, from -$925000.0 in the prior quarter.
In the past five years, Treasury Shares ranged from a high of -$943000.0 in Q2 2016 to a low of -$1.0 million in Q1 2014.
A 3-year average of -$993375.0 and a median of -$984500.0 in 2016 frame the typical range for Treasury Shares.
Annual changes were most pronounced in 2014 — Treasury Shares dropped 5.18% — and 2015, when it increased 8.72%.
Tracing CANF's Treasury Shares over 4 years: stood at -$1.0 million in 2013, then gained by 4.29% to -$982000.0 in 2014, then grew by 5.8% to -$925000.0 in 2015, then jumped by 204.86% to $970000.0 in 2016.
The last three Treasury Shares figures came in at $970000.0 (Q4 2016), -$925000.0 (Q3 2015), and -$963000.0 (Q2 2015), per Business Quant data.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Treasury Shares (Qtr)
1	Vertex Pharmaceuticals	139.29 Bn	131.44 Bn	2.84 Bn	-
2	Regeneron Pharmaceuticals	86.31 Bn	78.32 Bn	3.93 Bn	36.40 Mn
3	Argenx Se	65.22 Bn	60.03 Bn	1.37 Bn	-
4	Moderna	58.92 Bn	53.78 Bn	52.00 Mn	-
5	BeOne Medicines	42.07 Bn	36.97 Bn	1.53 Bn	-
6	Alnylam Pharmaceuticals	31.70 Bn	28.39 Bn	992.69 Mn	-
7	BioNTech SE	27.99 Bn	9.60 Bn	668.28 Mn	8.96 Mn
8	Insmed	27.51 Bn	26.35 Bn	358.27 Mn	-
9	Royalty Pharma	27.28 Bn	26.45 Bn	-	2.72 Mn
10	Can-Fite BioPharma	2.77 Mn	-8.78 Mn	-	-

Download Data